The Retinal Biologics Market is experiencing a surge in demand, fueled by advancements in eye disease treatments and a growing emphasis on vision health. According to a recent analysis by Future Market Insights (FMI), a leading market research firm, the market is currently valued at an impressive US$22.25 billion in 2022. Looking ahead, the market is projected to witness a remarkable Compound Annual Growth Rate (CAGR) of 11.1% over the next six years. This translates to a staggering market valuation of US$41.92 billion by 2028, highlighting the significant potential of retinal biologics in revolutionizing eye care.Todos los derechos reservados